Abstract: Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD4OL) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses.
Abstract: The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject.
Abstract: The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.
Type:
Application
Filed:
March 18, 2021
Publication date:
July 8, 2021
Applicant:
Bavarian Nordic A/S
Inventors:
Susan Foy, Stefanie Mandl, Ryan Rountree, Alain Delcayre
Abstract: The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.
Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
July 6, 2021
Assignee:
Bavarian Nordic A/S
Inventors:
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g.
Type:
Application
Filed:
March 15, 2021
Publication date:
July 1, 2021
Applicant:
Bavarian Nordic A/S
Inventors:
Cedric Cheminay, Robin Steigerwald, Paul Chaplin
Abstract: The present invention provides storage optimized aqueous compositions comprising a poxvirus suitable as poxvirus vaccine and pharmaceutical compositions, in particular liquid compositions or liquid frozen compositions, and methods of making them.
Abstract: The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof. The invention is drawn to compositions and methods for the induction of strong CD8 T cell and antibody responses to a specific antigen(s) by administering one or more immunizations of the recombinant MVA to a mammal, preferably a human.
Abstract: Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD40L) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses.
Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
March 16, 2021
Assignee:
Bavarian Nordic A/S
Inventors:
Cédric Cheminay, Robin Steigerwald, Paul Chaplin
Abstract: Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
Abstract: The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.
Abstract: Provided herein are recombinant poxviruses comprising heterologous or native nucleic acids specifying excess double-stranded RNA (dsRNA) early in infection, which may further comprise heterologous nucleic acids encoding one or more costimulatory molecules, and/or heterologous nucleic acids encoding one or more infectious disease-associated antigens or tumor-associated antigens, as well as pharmaceutical compositions comprising such recombinant poxviruses and methods and uses thereof. The recombinant poxviruses provided herein enhance innate and adaptive immune activation in subjects compared to identical recombinant poxviruses lacking heterologous or native transcription units specifying excess early dsRNA.
Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
Type:
Application
Filed:
August 23, 2018
Publication date:
October 1, 2020
Applicant:
Bavarian Nordic A/S
Inventors:
Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
Type:
Application
Filed:
February 27, 2020
Publication date:
August 27, 2020
Applicant:
Bavarian Nordic A/S
Inventors:
Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann
Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.
Type:
Application
Filed:
January 9, 2020
Publication date:
June 4, 2020
Applicant:
Bavarian Nordic A/S
Inventors:
Cédric Cheminay, Robin Steigerwald, Paul Chaplin
Abstract: The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to MVA can vastly increase the B cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens. Thus, the addition of an oil and water emulsion to MVA can increase the protective immune response. The invention encompasses administering a dose of an MVA in an oil and water emulsion to an animal, especially a human.
Type:
Grant
Filed:
March 12, 2015
Date of Patent:
May 19, 2020
Assignee:
Bavarian Nordic A/S
Inventors:
Cédric Cheminay, Robin Steigerwald, Ariane Volkmann
Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
Type:
Grant
Filed:
September 3, 2015
Date of Patent:
March 3, 2020
Assignee:
Bavarian Nordic A/S
Inventors:
Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann Hausmann
Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.
Type:
Application
Filed:
September 28, 2017
Publication date:
February 27, 2020
Applicant:
Bavarian Nordic A/S
Inventors:
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
Type:
Grant
Filed:
September 3, 2015
Date of Patent:
February 18, 2020
Assignees:
Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Services
Inventors:
Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward